AGIO falls 25% as Novo Nordisk sickle cell drug hits trial goals

Agios (AGIO) stock slumped 25% after Novo Nordisk's sickle cell drug met primary endpoints, raising competition concerns. This contrasts with Agios's Mitapivat, which failed key goals last November. Trust analysts believe Novo's strong results will hamper AGIO's ability to rebound to $40.